Aurobindo Splits Out Biosimilars Business
Firm Upbeat On Outlook As It Seeks FDA Desk Reviews For Three Units
After double-digit growth in formulations sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which it has now transferred to its fully-owned subsidiary for $48m.
